Executive Summary
Integrated DNA Technologies sought IPR of Tecan Genomics' patent covering nucleic acid technologies. The patent owner filed a terminal disclaimer of the entire patent, prompting the Board to grant an adverse judgment and terminate the proceeding.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Integrated DNA Technologies, Inc. et al. vs Tecan Group AG is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
DISH Network L.L.C. et al.vsEntropic Communications LLC
DISH Network filed a Director Review request after the PTAB denied institution of its IPR against Entropic Communications’ 8,631,450 patent. The petitioner claims the Board misapplied obviousness law by demanding a specific benefit, contrary to precedent, and seeks reversal.
Merck Sharp & Dohme LLCvsSurrozen Operating, Inc. et al.
Merck has filed a post‑grant review petition challenging U.S. Patent 12,297,278 covering broad tetravalent Wnt‑surrogate antibodies. The petition asserts lack of written description, enablement, indefiniteness, and anticipation by the Garcia publication.
PacifiCorp et al.vsMES, Inc.
MidAmerican Energy Company and BirchTech Corp. have settled their dispute over U.S. Patent 10,926,218 and jointly moved to terminate the inter partes review, citing statutory requirements and public‑policy benefits of settlement.
Wise PLC et al.vs--
The PTAB granted institution of an IPR on Intercurrency Software’s 10,776,863 patent covering a consolidated trading platform, finding a reasonable likelihood of unpatentability for claims 1‑12 based on obviousness over multiple prior‑art references.
GLOBALFOUNDRIES Inc. et al.vsOAK IP LLC
The Board instituted IPR2020‑01206 on 294 claims of the ’691 patent and held eight claims unpatentable for anticipation by Grupp ’483, while leaving the remaining claims intact.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.